194 related articles for article (PubMed ID: 37166744)
1. MAP3K1 expression is associated with progression and poor prognosis of hormone receptor-positive, HER2-negative early-stage breast cancer.
Kuo SH; Wei MF; Lee YH; Lin JC; Yang WC; Yang SY; Huang CS
Cell Oncol (Dordr); 2023 Oct; 46(5):1213-1234. PubMed ID: 37166744
[TBL] [Abstract][Full Text] [Related]
2. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
Carene D; Tran-Dien A; Lemonnier J; Dalenc F; Levy C; Pierga JY; Jacot W; Canon JL; Richon C; Lacroix L; Caux C; André F; Michiels S
Breast Cancer Res Treat; 2020 Jan; 179(2):387-401. PubMed ID: 31620934
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Kuo SH; Yang SY; You SL; Lien HC; Lin CH; Lin PH; Huang CS
Oncotarget; 2017 Mar; 8(13):20925-20938. PubMed ID: 28178648
[TBL] [Abstract][Full Text] [Related]
4. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
Le XF; Arachchige-Don AS; Mao W; Horne MC; Bast RC
Mol Cancer Ther; 2007 Nov; 6(11):2843-57. PubMed ID: 18025271
[TBL] [Abstract][Full Text] [Related]
5. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.
Hayashi N; Niikura N; Yamauchi H; Nakamura S; Ueno NT
Breast Cancer Res Treat; 2013 Jan; 137(2):523-31. PubMed ID: 23184079
[TBL] [Abstract][Full Text] [Related]
6. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.
Singel SM; Batten K; Cornelius C; Jia G; Fasciani G; Barron SL; Wright WE; Shay JW
Breast Cancer Res; 2014 Mar; 16(2):R28. PubMed ID: 24642040
[TBL] [Abstract][Full Text] [Related]
7. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma.
Davidson B; Konstantinovsky S; Kleinberg L; Nguyen MT; Bassarova A; Kvalheim G; Nesland JM; Reich R
Gynecol Oncol; 2006 Sep; 102(3):453-61. PubMed ID: 16494928
[TBL] [Abstract][Full Text] [Related]
8. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
9. Alcohol promotes migration and invasion of triple-negative breast cancer cells through activation of p38 MAPK and JNK.
Zhao M; Howard EW; Parris AB; Guo Z; Zhao Q; Yang X
Mol Carcinog; 2017 Mar; 56(3):849-862. PubMed ID: 27533114
[TBL] [Abstract][Full Text] [Related]
10. Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.
Rebbeck TR; DeMichele A; Tran TV; Panossian S; Bunin GR; Troxel AB; Strom BL
Carcinogenesis; 2009 Feb; 30(2):269-74. PubMed ID: 19028704
[TBL] [Abstract][Full Text] [Related]
11. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
[TBL] [Abstract][Full Text] [Related]
12. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
13. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract][Full Text] [Related]
14. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
16. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
17. IGFBP-1 Expression Promotes Tamoxifen Resistance in Breast Cancer Cells via Erk Pathway Activation.
Zheng Y; Sowers JY; Houston KD
Front Endocrinol (Lausanne); 2020; 11():233. PubMed ID: 32435229
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer.
Wu Y; Mohamed H; Chillar R; Ali I; Clayton S; Slamon D; Vadgama JV
Breast Cancer Res; 2008; 10(1):R3. PubMed ID: 18184439
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of cyclin-dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1.
Bhowmik T; Gomes A
Chem Biol Interact; 2017 Apr; 268():119-128. PubMed ID: 28322778
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]